Clinical trials: Stage II Prostate Cancer
Prostate Cancer
Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)
This is a Phase II study to test the efficacy of exogenously administered GM-CSF in prostate cancer patients who have failed definitive local therapy, and have only serologic (PSA) evidence of progression.
- Trial name
- NCT00678054
- Testing
- GM-CSF
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Breast Cancer, Non Small Cell Lung Cancer
Metronomic Oral Vinorelbine in Patients With Metastatic Tumors
Patients with recurrent or metastatic solid tumors receive oral vinorelbine at one of three different doses (30 or 40 or 50 mg).
- Conditions
- Breast Cancer, Non Small Cell Lung Cancer, Prostate Cancer
- Trial name
- NCT00278070
- Testing
- vinorelbine oral formulation
- Where
- 11 sites in Greece
- Sponsor
- Hellenic Cooperative Oncology Group
Metastatic Cancer, Prostate Cancer
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as goserelin and leuprolide may fight prostate cancer by stopping the adrenal glands from producing androgens.
- Trial name
- NCT00081159
- Testing
- Doxorubicin hydrochloride, Goserelin acetate, Leuprolide acetate
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating men who have stage IV…
- Trial name
- NCT00005820
- Testing
- nitrocamptothecin
- Where
- 50 sites in United States
- Volunteers
- 35 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Nutrition and Lifestyle Changes in Patients With Previously Untreated Stage I or Stage II Prostate Cancer
RATIONALE: Learning about changes in DNA over time in patients with prostate cancer undergoing diet and lifestyle changes may help doctors learn about the long-term effects of these changes on disease progression.
- Trial name
- NCT00739791
- Testing
- exercise intervention, gene expression analysis, polymerase chain reaction
- Volunteers
- 34 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Study of Blood and Tumor Samples From Men With an Inherited Risk of Prostate Cancer
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify genes related to cancer.
- Trial name
- NCT00959023
- Testing
- laboratory biomarker analysis, medical chart review, questionnaire administration
- Where
- 135 sites in United Kingdom
- Volunteers
- 21,000 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Prostatic Neoplasms
A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer
The aim of this study was to evaluate the efficacy of two different doses of BIBF 1120 (250 mg twice daily versus 150 mg twice daily) in an exploratory manner.
- Trial name
- NCT02182063
- Testing
- BIBF 1120 low dose, BIBF 1120 high dose
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim
Prostate Cancer
Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer
RATIONALE: Testosterone can stimulate the growth of cancer cells. Bicalutamide and goserelin may fight prostate cancer by reducing the production of testosterone.
- Trial name
- NCT00014586
- Testing
- bicalutamide, goserelin acetate, orchiectomy
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
Dietary Intervention With Phytochemicals and Polyunsaturated Fatty Acids in Prostate Cancer Patients
We will study the effect of dietary intervention in patients with prostate cancer. Outcomes include serum PSA kinetics, as well as biomarkers of inflammation, antioxidant status, oxidative stress and oxidative damage in blood…
- Trial name
- NCT00433797
- Testing
- Prostate cancer, phytochemical and PUFA
- Where
- Norway
- Volunteers
- 86 people
- Sponsor
- University of Oslo
Male Erectile Disorder, Prostate Cancer
Focal Therapy for Prostate Cancer Using HIFU
RATIONALE: Prospective trials using hemi-ablation with high intensity focused ultrasound (HIFU) (Sonablate 500) have demonstrated feasibility, safety, and encouraging functional outcomes and early cancer control with 90% of men…
- Conditions
- Male Erectile Disorder, Prostate Cancer, Therapy-related Toxicity, Urinary Incontinence
- Trial name
- INDEX (NCT01194648)
- Testing
- questionnaire administration, assessment of therapy complications, high-intensity focused ultrasound ablation
- Where
- United Kingdom
- Volunteers
- 354 people
- Sponsor
- University College, London
Bone Metastases, Castrate-resistant Prostate Cancer
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer
This study is being done to help researchers understand more about prostate cancer that has spread to the bones by using the newest magnetic resonance imaging (MRI) techniques and to better understand the effect of an…
- Conditions
- Bone Metastases, Castrate-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01599793
- Testing
- cabozantinib, laboratory biomarker analysis, magnetic resonance imaging
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Chicago
Prostate Cancer
Fulvestrant in Treating Patients With Recurrent Prostate Cancer
RATIONALE: Estrogen may cause the growth of prostate cancer cells. Hormone therapy using fulvestrant may fight prostate cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00217464
- Testing
- fulvestrant
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer, Cervical Cancer
Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Breast Cancer, Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer
- Trial name
- NCT00601406
- Testing
- gene expression analysis, gene rearrangement analysis, polymorphism analysis
- Where
- 11 sites in United Kingdom
- Volunteers
- 2,200 people
- Sponsor
- The Christie NHS Foundation Trust
Prostate Cancer
ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of prostate cancer.
- Trial name
- NCT00025116
- Testing
- gefitinib
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- NCIC Clinical Trials Group
Prostate Cancer
Stereotactic Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00619515
- Testing
- questionnaire administration, implanted fiducial-based imaging, stereotactic radiosurgery
- Where
- 4 sites in United States
- Volunteers
- 73 people
- Sponsor
- Case Comprehensive Cancer Center
Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
This randomized phase II trial studies how well androgen receptor antagonist ARN-509 works with or without abiraterone acetate, gonadotropin-releasing hormone agonist, and prednisone in treating patients with high-risk prostate…
- Trial name
- NCT02949284
- Testing
- Abiraterone Acetate, Androgen Receptor Antagonist ARN-509, Gonadotropin-releasing Hormone Analog
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Rutgers, The State University of New Jersey
Prostate Cancer, Anemia
Study of Aranesp to Treat Anemia in Prostate Cancer Patients.
The purpose of this study is to see if darbepoetin alfa is an effective treatment for anemia in prostate cancer patients and, if so, what dose is most effective.
- Trial name
- NCT00245895
- Testing
- Aranesp
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Washington
Prostate Cancer
GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer
RATIONALE: Colony-stimulating factors, such as GM-CSF, may help the body build an effective immune response to kill tumor cells. Giving GM-CSF before surgery may be an effective treatment for localized prostate cancer.
- Trial name
- NCT00305669
- Testing
- sargramostim, immunohistochemistry staining method, immunological diagnostic method
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Study of a Polymorphism in Patients With Prostate Cancer
RATIONALE: Studying samples of blood from patients with cancer and from healthy participants in the laboratory may help doctors learn more about changes that may occur in DNA.
- Trial name
- NCT00900185
- Testing
- mutation analysis, polymerase chain reaction, polymorphism analysis
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have stage IV…
- Trial name
- NCT00004149
- Testing
- arsenic trioxide
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Albert Einstein College of Medicine